{"entity":{"id":"nct06722183","kind":"trial","name":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","aka":["FUTURE"],"tldr":"A phase 2 trial of tislelizumab in colorectal cancer, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, now recruiting.","summary":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities is a phase 2, interventional study registered as NCT06722183 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 33 participants, started 2025-12-16 and due to reach its primary completion in 2028-03. Interventions recorded: Futibatinib orally administered; Tislelizumab (i.v. 200mg). Conditions listed: Colorectal Cancer. Primary outcome: Overall Response Rate (ORR) according to RECIST v1.1. Colorectal eligibility wording from the registry: \"• Specific for FUTURE-001: Histological or cytological confirmation of colorectal adenocarcinoma that is unresectable and/or metastatic with known RAS-, BRAF and MSI- status\". Sites: Germany. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06722183","url":"https://clinicaltrials.gov/study/NCT06722183"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06722183","phase":"2","setting":"FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06722183/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}